Peginterferon alfa-2a and ribavirin combination therapy in patients with HBeAg [hepatitis B envelope antigen]-negative chronic HBV [hepatitis B virus] infection (PARC Study).

Trial Profile

Peginterferon alfa-2a and ribavirin combination therapy in patients with HBeAg [hepatitis B envelope antigen]-negative chronic HBV [hepatitis B virus] infection (PARC Study).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms PARC
  • Most Recent Events

    • 11 May 2010 Results were published in the American Journal of Gastroenterology.
    • 15 Feb 2008 Status changed from recruiting to completed; according to Roche.
    • 16 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top